Nanox Announces Live Demonstration of its Nanox.ARC System at Radiology Society of North America (RSNA) 2020

Nanox Announces Live Demonstration of its Nanox.ARC System at Radiology
Society of North America (RSNA) 2020

NEVE ILAN,  Israel, Oct.  01,  2020 (GLOBE  NEWSWIRE)  -- NANO-X  IMAGING  LTD
(NASDAQ: NNOX)  (“Nanox”  or the  “Company”),  an innovative  medical  imaging
technology company, is pleased to announce today that it will demonstrate  its
novel technology (Nanox.SOURCE) and medical imaging system (Nanox.ARC) at RSNA
2020, which is being held November 29-December 5 in Chicago.

The demonstration will  include a  technology section  elaborating on  Nanox’s
first commercial-grade digital x-ray source  followed by a live  demonstration
of the Nanox.ARC in a range of 2D and 3D medical imaging procedures.

The demonstration  will  be led  by  Mr.  Ran Poliakine,  Chairman  and  Chief
Executive Officer  of Nanox,  and  will be  live  streamed globally.  It  will
include  a  professional  radiology  Q&A  session  followed  by  lectures  and
presentations of clinical applications of the Nanox.ARC medical imaging system
by well-known radiologists and Company distribution partners.

Mr. Poliakine stated: “We are pleased to invite everyone to witness first-hand
our technology and the  Nanox.ARC at the  RSNA. We have  an ambitious goal  of
making  medical  imaging  widely  available  on  a  global  basis  to  promote
preventive healthcare  through  early  detection. Two-thirds  of  the  world’s
population currently have no access to medical imaging, and we aim to  improve
this statistic. We look forward to this demonstration which will allow  people
to see the depth and validity of our technology.”

About Nanox:

Nanox, founded  by  the  serial  entrepreneur Ran  Poliakine,  is  an  Israeli
corporation  that  is  developing  a  commercial-grade  digital  X-ray  source
designed to be used in real-world medical imaging applications. Nanox believes
that its  novel technology  could significantly  reduce the  costs of  medical
imaging systems and plans to seek collaborations with world-leading healthcare
organizations and  companies to  provide affordable,  early detection  imaging
service for all. For more information, please visit

Forward-Looking Statements:

This press release may contain forward-looking statements that are subject to
risks and uncertainties. All statements that are not historical facts
contained in this press release are forward-looking statements. Such
statements include, but are not limited to, any statements relating to the
initiation, timing, progress and results of Nanox's research and development,
manufacturing and commercialization activities with respect to its X-ray
source technology and the Nanox.ARC. In some cases, you can identify
forward-looking statements by terminology such as “can,” “might,” “believe,”
“may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,”
“should,” “could,” “expect,” “predict,” “potential,” or the negative of these
terms or other similar expressions. Forward-looking statements are based on
information Nanox has when those statements are made or management's good
faith belief as of that time with respect to future events, and are subject to
risks and uncertainties that could cause actual performance or results to
differ materially from those expressed in or suggested by the forward-looking
statements. Factors that could cause actual results to differ materially from
those currently anticipated include: risks related to business interruptions
resulting from the COVID-19 pandemic or similar public health crises could
cause a disruption of the development, deployment or regulatory clearance of
the Nanox System and adversely impact our business; Nanox's ability to
successfully demonstrate the feasibility of its technology for commercial
applications; Nanox's expectations regarding the necessity of, timing of
filing for, and receipt and maintenance of, regulatory clearances or approvals
regarding its X-ray source technology and the Nanox.ARC from regulatory
agencies worldwide and its ongoing compliance with applicable quality
standards and regulatory requirements; Nanox's ability to enter into and
maintain commercially reasonable arrangements with third-party manufacturers
and suppliers to manufacture the Nanox.ARC; the market acceptance of the
Nanox.ARC and the proposed pay-per-scan business model; Nanox's expectations
regarding collaborations with third-parties and their potential benefits; and
Nanox's ability to conduct business globally, among others. Except as required
by law, Nanox undertakes no obligation to update publicly any forward-looking
statements after the date of this press release to conform these statements to
actual results or to changes in Nanox's expectations.


Itzhak Maayan
Nanox Imaging
[email protected]

Bob Yedid
LifeSci Advisors
[email protected]


Source Article